Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovitis, progressive joint damage, and considerable heterogeneity in disease evolution and treatment response. The concept of theranostic nanoprobes has recently moved beyond multifunctional carriers that simply package imaging and therapeutic agents; instead, these platforms are being designed to establish an integrated imaging-therapy-feedback loop that enables disease-specific targeting, real-time molecular visualization, on-demand intervention, and dynamic monitoring of treatment effects-all within a single system. This review traces the evolution of RA theranostic nanoprobes along this trajectory, from molecular targeting and inflammation imaging, through therapeutic delivery and response monitoring, toward adaptive precision management. We first outline the pathological and biological features that enable selective homing to inflamed joints and subsequent molecular imaging of disease activity. We then survey current therapeutic strategies-including anti-inflammatory drug delivery, immunomodulation, redox regulation, and phototherapy-with an emphasis on how these modalities are being functionally coupled with imaging capabilities to support image-guided intervention and treatment feedback. Building on these advances, we propose a conceptual framework that distinguishes fully integrated theranostic platforms from conventional diagnostic nanoprobes and therapeutic nanocarriers. While preclinical progress has been substantial, clinical translation remains hindered by outstanding challenges in long-term safety, biodistribution, repeat-dose compatibility, manufacturing reproducibility, regulatory complexity, and validation against established clinical endpoints. Future advances will require not only improved nanoparticle design but also standardized translational evaluation and closer integration with clinically relevant disease-assessment strategies.